[Immunomodulating action of eubiotics].
The study was undertaken to study the immunomodulating action of 3 bacterial agents: bifidumbacterin, acylact, and biosporine used in various abnormalities accompanied by intestinal dysbacteriosis. Surveys were made of children permanently residing in the radionuclide-contaminated areas of the Bryansk Region, those from northern areas of the Russian Federation, those who suffered from atopic dermatitis; adult patients with severe systemic disease (chronic postinfection polyarthritis); chronic adult patients with spinal injury due to compression fractures of the spinal cord. The immunological parameters in all the above patient groups were shown to differ in the lower absolute or relative counts of most lymphocytic populations. The addition of bacterial drugs into their therapy promoted normalization of the intestinal microflora and led to improvement or complete normalization of immunological parameters. With this, bifidumbacterin and acylact were demonstrated to be potent, but mild immunomodulators as they significantly improved or normalized the status of the baseline suppressed immune system and virtually failed to affect normal immunological parameters. The earlier data obtained with biosporine provide evidence for that this bacterial agent has immunomodulating activity; however, it is necessary to comprehensively study its effects on the immune system in health and in disorders typical of various abnormalities.
Lopatina
T K
TK
NII of Epidemiology and Microbiology of GN Gabrichevskií, Moscow.
Bliakher
M S
MS
Nikolaenko
V N
VN
Nilovskií
M N
MN
Pozhalostina
L V
LV
Rubtsov
O V
OV
Rokosueva
L A
LA
Petrova
N V
NV
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D001688:Biological Products / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004064:Digestive System / Q000187:drug effects / Q000276:immunology / Q000382:microbiology; D006801:Humans; D007109:Immunity / Q000187:drug effects*
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D001688:Biological Products